title: [Clinical-hemodynamic and anti-ischemic effects ivabradine and nebivolol ischemic heart disease with left ventricular dysfunction].
abstract: The aim of this study was to examine the effectiveness of Ivabradine (available under the brandnames of Procoralan, Coralan, Corlentor, Coraxan, "Servier", France) and Nebivolol (Nebilet, "Berlin-Chemie", Germany) with combination of standard therapy in patients with coronary artery disease and left ventricular dysfunction. A total of 72 patients (mean age 57.3±4,5 years) have been observed during 6 months. Patients were divided into 3 groups (standard therapy; standard therapy and Nebilet; standard therapy and Coraxan). The results showed that Coraxan with combination therapy compared optimally reduced heart rate and ensure a proper anti-ischemic effect, expressed as reduced left ventricular dysfunction, improved the degree of congestive heart failure than the group Nebilet.
authors.forename: G V
authors.initials: GV
authors.lastname: Abuladze
authors.forename: A A
authors.initials: AA
authors.lastname: Kvirkveliia
authors.forename: M I
authors.initials: MI
authors.lastname: Nebieridze
authors.forename: T B
authors.initials: TB
authors.lastname: Chachua
authors.forename: G I
authors.initials: GI
authors.lastname: Dundua
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists / Q000627:therapeutic use*; D001552:Benzazepines / Q000627:therapeutic use*; D001578:Benzopyrans / Q000627:therapeutic use*; D004562:Electrocardiography; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006439:Hemodynamics; D006801:Humans; D000077550:Ivabradine; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D000068577:Nebivolol; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D001552:Benzazepines; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol; D000077550:Ivabradine